What is HC Wainwright’s Estimate for HRTX Q1 Earnings?

Heron Therapeutics, Inc. (NASDAQ:HRTX) – Analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Heron Therapeutics in a note issued to investors on Thursday, February 26th. HC Wainwright analyst B. Folkes forecasts that the biotechnology company will post earnings of ($0.03) per share for the quarter. HC Wainwright has a “Buy” rating and a $6.00 price target on the stock. The consensus estimate for Heron Therapeutics’ current full-year earnings is ($0.13) per share. HC Wainwright also issued estimates for Heron Therapeutics’ Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.01) EPS, Q4 2026 earnings at $0.00 EPS, FY2027 earnings at $0.14 EPS, FY2028 earnings at $0.39 EPS, FY2029 earnings at $0.44 EPS and FY2030 earnings at $0.55 EPS.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, January 22nd. Jefferies Financial Group restated a “buy” rating on shares of Heron Therapeutics in a report on Tuesday, November 4th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $4.50.

Heron Therapeutics Price Performance

Heron Therapeutics stock opened at $1.19 on Friday. The business’s 50-day simple moving average is $1.30 and its 200 day simple moving average is $1.27. The company has a quick ratio of 1.78, a current ratio of 2.56 and a debt-to-equity ratio of 19.89. The stock has a market cap of $218.20 million, a price-to-earnings ratio of -9.15 and a beta of 1.25. Heron Therapeutics has a 12-month low of $1.00 and a 12-month high of $2.68.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to analyst estimates of $39.53 million.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Rubric Capital Management LP raised its holdings in Heron Therapeutics by 3.3% in the fourth quarter. Rubric Capital Management LP now owns 30,046,828 shares of the biotechnology company’s stock worth $39,061,000 after purchasing an additional 946,100 shares during the period. Clearline Capital LP increased its position in shares of Heron Therapeutics by 26.0% in the 4th quarter. Clearline Capital LP now owns 12,235,239 shares of the biotechnology company’s stock valued at $15,906,000 after buying an additional 2,522,712 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its stake in Heron Therapeutics by 9.2% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 11,185,325 shares of the biotechnology company’s stock worth $14,541,000 after buying an additional 946,100 shares during the period. Velan Capital Investment Management LP raised its stake in Heron Therapeutics by 25.3% during the 3rd quarter. Velan Capital Investment Management LP now owns 8,753,290 shares of the biotechnology company’s stock worth $11,029,000 after buying an additional 1,766,546 shares during the period. Finally, Millennium Management LLC lifted its holdings in Heron Therapeutics by 2,785.2% during the fourth quarter. Millennium Management LLC now owns 7,169,908 shares of the biotechnology company’s stock worth $9,321,000 after acquiring an additional 6,921,405 shares in the last quarter. Institutional investors and hedge funds own 80.01% of the company’s stock.

Heron Therapeutics News Roundup

Here are the key news stories impacting Heron Therapeutics this week:

• Positive Sentiment: Q4 results and company guidance: Heron reported Q4 revenue of $40.59M and EPS of ($0.02), both modest beats vs. Street estimates, and reported full‑year 2025 net revenue of $154.9M (65% YoY growth driven by ZYNRELEF and APONVIE). Management issued FY2026 net revenue guidance of $173–$183M and adjusted EBITDA guidance of $10–$20M — a clear near‑term commercial growth signal. Heron Press Release
• Positive Sentiment: HC Wainwright reiterates Buy and $6 target: Analyst B. Folkes continues to rate HRTX a Buy and models a multi‑year recovery to profitability (FY2027+), including an eventual FY2030 EPS of $0.55 — signaling meaningful upside from current levels if execution and product growth continue. (HC Wainwright research note)
• Neutral Sentiment: HC Wainwright near‑term modeling: The firm provided detailed Q1–Q4 2026 EPS estimates (Q1 -$0.03, Q2 -$0.02, Q3 -$0.01, Q4 $0.00) and a FY2026 consensus around -$0.13 — useful visibility but not an immediate catalyst. (HC Wainwright research note)
• Neutral Sentiment: Coverage and takeaways from the quarter are circulating: earnings call highlights and analyst write‑ups summarize the beat, commercial momentum, and guidance. These pieces help investors parse the quarter but largely echo the company release. Earnings Call Highlights Zacks Analysis WTOP Snapshot
• Negative Sentiment: Modest medium‑term EPS downgrades from HC Wainwright: The analyst trimmed FY2027, FY2028 and FY2029 EPS forecasts slightly (FY2027 to $0.14 from $0.15; FY2028 to $0.39 from $0.43; FY2029 to $0.44 from $0.48). Those cuts reduce some of the upside implied by prior estimates and may have tempered enthusiasm after recent share gains. (HC Wainwright research note)

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.